National Comprehensive Cancer Network receives research grant to evaluate pralatrexate in solid tumors and hematologic malignancies

Source; au.sys-con.com Author: PRNewswire press release The National Comprehensive Cancer Network (NCCN) has been awarded a research grant from Allos Therapeutics, Inc. to support clinical studies of pralatrexate (FOLOTYN(TM), Allos Therapeutics, Inc.) in the treatment of select hematologic malignancies and solid tumors. Pralatrexate was recently approved by the FDA to treat patients with relapsed or refractory [...]